TY - JOUR
T1 - Functional or radical surgical treatment of laryngeal chondrosarcoma, analysis of survival and prognostic factors
T2 - A REFCOR and NetSarc-ResOs multicenter study of 74 cases
AU - Gazda, Pierre
AU - Baujat, Bertrand
AU - Sarini, Jérôme
AU - Gomez-Brouchet, Anne
AU - Philouze, Pierre
AU - Moya-Plana, Antoine
AU - Malard, Olivier
AU - Fakhry, Nicolas
AU - De Mones Del Pujol, Erwan
AU - Garrel, Renaud
AU - Page, Cyril
AU - Mouawad, Francois
AU - Vaz, Emmanuelle
AU - Evrard, Diane
AU - Bach, Christine
AU - Dufour, Xavier
AU - Lelonge, Yann
AU - Schultz, Philippe
AU - Mauvais, Olivier
AU - Brenet, Esteban
AU - Vergez, Sébastien
AU - Atallah, Sarah
N1 - Publisher Copyright:
© 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Introduction: Laryngeal chondrosarcoma (LCS) is a rare tumor of slow evolution whose treatment is poorly codified. For a long time, a radical treatment by total laryngectomy (TL) was proposed. More recent studies tend to propose a conservative surgical approach of the larynx. The objective of this study was to compare the overall survival (OS) of total laryngectomized patients (TL+) versus non-laryngectomized patients (TL-). The secondary objectives were to analyse the reoperation free survival (RFS), the total laryngectomy free survival (TLFS) and to identify the preoperative factors leading surgeons to propose TL. Materials and methods: A retrospective analysis of prospectively collected incident cases from the REFCOR and NetSarc-ResOs multicenter databases between March 1997 and June 2021 was conducted. A propensity score matching analysis was performed to compare the OS of TL+ and TL-patients. Results: 74 patients were included. After propensity score, the 5-year OS of TL+ and TL-patients was comparable (100 %, p = 1). The 5-year RFS rate was 69.2 % (95 % CI [57.5–83.4]) and the 5-year TLFS was 61.7 % (95 % CI [50.4–75.5]). Cricoid involvement greater than 50 % (HR 3.58; IC 95 % [1.61–7.92] p < 0.001), an ASA score of 3 or 4 (HR 5.07; IC 95 % [1.64–15.67] p = 0.009) and involvement of several cartilages (HR 5.26; IC 95 % [1.17–23.6] p = 0.04) are prognostic factors for TL. Dyspnea caused by the tumour is a prognostic factor for reoperation (HR 2.59; IC 95 % [1.04–6.45] p = 0.03). Conclusion: These results demonstrate that conservative treatment should be considered as first-line treatment for laryngeal chondrosarcoma.
AB - Introduction: Laryngeal chondrosarcoma (LCS) is a rare tumor of slow evolution whose treatment is poorly codified. For a long time, a radical treatment by total laryngectomy (TL) was proposed. More recent studies tend to propose a conservative surgical approach of the larynx. The objective of this study was to compare the overall survival (OS) of total laryngectomized patients (TL+) versus non-laryngectomized patients (TL-). The secondary objectives were to analyse the reoperation free survival (RFS), the total laryngectomy free survival (TLFS) and to identify the preoperative factors leading surgeons to propose TL. Materials and methods: A retrospective analysis of prospectively collected incident cases from the REFCOR and NetSarc-ResOs multicenter databases between March 1997 and June 2021 was conducted. A propensity score matching analysis was performed to compare the OS of TL+ and TL-patients. Results: 74 patients were included. After propensity score, the 5-year OS of TL+ and TL-patients was comparable (100 %, p = 1). The 5-year RFS rate was 69.2 % (95 % CI [57.5–83.4]) and the 5-year TLFS was 61.7 % (95 % CI [50.4–75.5]). Cricoid involvement greater than 50 % (HR 3.58; IC 95 % [1.61–7.92] p < 0.001), an ASA score of 3 or 4 (HR 5.07; IC 95 % [1.64–15.67] p = 0.009) and involvement of several cartilages (HR 5.26; IC 95 % [1.17–23.6] p = 0.04) are prognostic factors for TL. Dyspnea caused by the tumour is a prognostic factor for reoperation (HR 2.59; IC 95 % [1.04–6.45] p = 0.03). Conclusion: These results demonstrate that conservative treatment should be considered as first-line treatment for laryngeal chondrosarcoma.
KW - Chondrosarcoma
KW - Laryngeal cancer
KW - Laryngeal preservation
KW - Larynx
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85182362389&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2023.107315
DO - 10.1016/j.ejso.2023.107315
M3 - Article
C2 - 38219696
AN - SCOPUS:85182362389
SN - 0748-7983
VL - 50
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 2
M1 - 107315
ER -